Company Island Pharmaceuticals Limited

Equities

ILA

AU0000138869

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 12:29:18 06/03/26 pm AEDT			5-day change	1st Jan Change
0.4050 ^AUD	-2.41%		+9.46%	-5.81%

04/03	Daily Special: Island Pharmaceuticals, GenusPlus Group, Horizon Gold	FI
04/03	Island Pharmaceuticals Enters Agreement to Advance Galidesivir Approval, Shares Up 19%	MT

Business description: Island Pharmaceuticals Limited

Island Pharmaceuticals Ltd is an Australia-based drug repurposing company. The Company is focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Its lead asset is ISLA-101, a drug with a safety profile, being repurposed for the prevention and treatment of dengue2 fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. While ISLA-101 is an oral formulation, the Company is also considering alternative formulations, including a long-acting oral formulation and intravenous formulations for severe dengue infections. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.

Sales by Activity: Island Pharmaceuticals Limited

Fiscal Period: June	2021 (AUD)	2022 (AUD)	2023 (AUD)	2024 (AUD)	2025 (AUD)
Pharmaceuticals	-	-	11.06K	1.27M	119K

See all business segments

Geographical breakdown of sales: Island Pharmaceuticals Limited

Fiscal Period: June	2021 (AUD)	2022 (AUD)	2023 (AUD)	2024 (AUD)	2025 (AUD)

See all geographic segments

Executive Committee: Island Pharmaceuticals Limited

Manager	Title	Age	Since
David Foster CEO	Chief Executive Officer	-	18/01/2021
Cameron Jones DFI	Director of Finance/CFO	-	-
Jane Lowe IRC	Investor Relations Contact	-	-

See ISLAND PHARMACEUTICALS LIMITED governance

Composition of the Board of Directors: Island Pharmaceuticals Limited

Director	Title	Age	Since
David Foster BRD	Director/Board Member	-	18/01/2021
Christopher Ntoumenopoulos BRD	Director/Board Member	-	19/09/2024
Jason Carroll CHM	Chairman	-	02/07/2025

Composition of the Board of Directors

Shareholders: Island Pharmaceuticals Limited

Name	Equities	%	Valuation
Garner William 15.5 %	41,690,073	15.5 %	11 M $
Jason Alan Carroll 11.92 %	32,074,930	11.92 %	9 M $
Daniel Tillett 7.795 %	20,973,789	7.795 %	6 M $
Mwp Partners Ltd. 7.16 %	19,264,773	7.16 %	5 M $
David Foster 2.418 %	6,504,460	2.418 %	2 M $

List of ISLAND PHARMACEUTICALS LIMITED shareholders

Company details: Island Pharmaceuticals Limited

Island Pharmaceuticals Ltd.

697 Burke Road

3124, Camberwell

http://www.islandpharmaceuticals.com

address Island Pharmaceuticals Limited(ILA)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ISLAND PHARMACEUTICALS LIMITED	-2.41%	+9.46%	+153.12%	+350.00%	88.48M
ARGENX SE	-2.55%	-3.99%	+5.71%	+92.32%	45.72B
WUXI APPTEC CO., LTD.	+0.47%	-5.67%	+54.34%	+11.05%	39.82B
INSMED INCORPORATED	-4.21%	-4.29%	+85.13%	+596.94%	32.31B
BIONTECH SE	-1.78%	-6.30%	-11.17%	-22.04%	26.05B
WUXI BIOLOGICS (CAYMAN) INC.	+0.51%	-11.79%	+50.66%	-38.03%	18.68B
GENMAB A/S	-1.03%	-3.24%	+7.28%	-30.72%	17.17B
AKESO, INC.	+2.84%	-1.96%	+45.76%	+141.20%	11.23B
SUMMIT THERAPEUTICS INC.	-2.86%	-5.44%	-23.58%	+870.13%	11.93B
EXELIXIS, INC.	-0.98%	-6.78%	+6.80%	+140.70%	10.83B
Average	-1.25%	-4.00%	+37.41%	+211.16%	21.38B
Weighted average by Cap.	-1.45%	-5.82%	+29.35%	+166.74%